Investigational Therapeutics That Restore Brain Synapses
Spinogenix is pioneering first-in-class, investigational therapeutics that restore brain synapses to improve the lives of patients worldwide.
A New Approach to the Brain’s Lost Connections
Spinogenix has designed small molecules to help restore the brain connections (synapses) in neurodegenerative, neuropsychiatric and neurodevelopmental conditions including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, schizophrenia, Fragile X Syndrome (FXS) and many others.
Latest Press Releases
Spinogenix Appoints Professor Joseph T. Coyle, MD, Current Chair of Psychiatry and Neuroscience at Harvard Medical School, to Scientific Advisory Board
July 2, 2026
Prof. Coyle to Provide Guidance on Company’s Neuroscience Pipeline, with Emphasis on Schizophrenia LOS ANGELES, July 2, 2026 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve...
Spinogenix Recognizes Dr. Craig Erickson following $17.25 Million Autism Research Grant to Cincinnati Children’s Hospital
June 15, 2026
Grant Will Support Spinogenix Chief Medical Advisor’s Research into Precision Medicine and EEG LOS ANGELES, June 15, 2026 – Spinogenix, Inc., a clinical-stage biopharmaceutical company pioneering novel therapeutics that have the potential to restore synapses to improve...
Spinogenix Receives U.S. FDA Fast Track Designation for Tazbentetol for the Treatment of ALS
May 5, 2026
Designation Enables an Enhanced Development Path for Tazbentetol and Underscores the Unmet Need for New Treatments In ALS Milestone Follows Recent Announcement of Phase 2a Results Showing Preliminary Evidence that...
In the News
Spinogenix’s Alzheimer’s drug touts disease-modifying potential in Phase IIa study
December 9, 2025
Topline data from a completed phase 2a trial (NCT05882695) highlighted the therapeutic benefits of SPG302, a synaptic regenerative drug, to treat patients with amyotrophic lateral sclerosis (ALS). All told, treatment...
From the Blog
Rethinking Alzheimer’s Treatment: It’s Time for a New Playbook in the Fight for Memory
December 1, 2025
Authored by Stella Sarraf, PhD CEO, Founder In September, we recognized World Alzheimer’s Month and championed the much-needed attention and awareness to one of the greatest health crises of our...